20 articles
50 nm polystyrene nanoplastics accumulate in mouse testes, degrading sperm quality and triggering iron-dependent cell death through a newly identified mitochondrial pathway.
Tebipenem pivoxil becomes the first oral carbapenem approved in the US, offering a non-IV option for serious UTIs.
A new ESRRA-ATG5 axis links mitochondrial recycling to arginine metabolism, and a plant polyphenol activates it to protect diabetic kidneys.
A comprehensive review finds SGLT2 inhibitors reduce AKI risk in humans via hemodynamic, metabolic, and cellular protective pathways.
New research links a simple urine marker to fatty liver disease, potentially enabling early detection and prevention.
A landmark RCT shows finerenone reduces eGFR decline and kidney-cardiovascular events in CKD patients without diabetes.
Landmark CKD trials enrolled mostly overweight patients — new evidence questions whether SGLT2 inhibitors work for lean, non-diabetic individuals.
Natural polyketide from marine bacteria enhances cholesterol removal and improves fat metabolism in liver cells and mice.
A Phase IIa trial explores whether the HIF-PHI drug daprodustat can safely replace EPO injections in hemodialysis patients with anemia.
Scientists discover urinary biomarker that reveals kidney scarring in diabetics years before traditional tests show damage.
Scientists identify how a metabolic enzyme drives kidney inflammation in diabetes, opening doors for targeted therapies.
Baxdrostat becomes the first-in-class aldosterone synthase inhibitor approved to treat resistant hypertension alongside existing drugs.
Inclisiran safely reduced LDL cholesterol by 28% in adolescents with familial hypercholesterolemia, offering hope for early intervention.
A genomic study of 3,358 biopsy-proven MASLD patients finds APOB pathogenic variants linked to significantly higher steatosis and liver injury scores.
New JAMA research suggests reducing dietary protein may slow kidney disease progression and improve patient outcomes.
New research reveals how RAP1A protein regulates liver blood vessel function and may influence fibrosis progression in chronic liver disease.
Survey of 89 Italian kidney specialists shows inconsistent approaches to treating bone disease in chronic kidney disease patients.
A systematic review of 38 trials finds tirzepatide cuts HbA1c nearly 3x more than lixisenatide with similar GI side effect rates.
New study reveals how the diabetes drug dapagliflozin dramatically alters fat metabolism and kidney function through previously unknown pathways.
Updated review of anti-obesity medications in MASLD finds GLP-1 agonists reduce steatosis and fibrosis, while newer dual/triple agonists show even greater metabolic promise.
